Medical device company Integra LifeSciences (NASDAQ: IART) met Wall Street’s revenue expectations in Q3 2026, with sales up 2.3% year on year to $411.2 million. On the other hand, next quarter’s revenue guidance of $423 million was less impressive, coming in 2.4% below analysts’ estimates. Its non-GAAP profit of $0.59 per share was 5.5% above analysts’ consensus estimates.
Is now the time to buy IART? Find out in our full research report (it’s free for active Edge members).
Integra LifeSciences (IART) Q3 2026 highlights:
- Revenue: $411.2 million vs analyst estimates of $412.6 million (2.3% year-on-year growth, in line)
- Adjusted EPS: $0.59 vs analyst estimates of $0.56 (5.5% beat)
- Adjusted EBITDA: $79.79 million vs analyst estimates of $83.25 million (19.4% margin, 4.2% miss)
- Revenue Guidance for Q4 2026 is $423 million at the midpoint, below analyst estimates of $433.2 million
- Management lowered its full-year Adjusted EPS guidance to $2.35 at the midpoint, a 4.1% decrease
- Operating Margin: 4.6%, down from 9.9% in the same quarter last year
- Organic Revenue rose 2.5% year on year (miss)
- Market Capitalization: $920.8 million
StockStory’s take
Integra LifeSciences’ third quarter was met with a negative market reaction, as operational disruptions and mixed segment performance clouded otherwise steady execution. Management highlighted that a significant flooding event at the Cincinnati facility posed greater-than-expected headwinds, particularly impacting the MAYFIELD neurosurgery product line and leading to a reduction in revenue. CEO Stuart Essig described the disruption as “more significant than initially expected,” with the company relying on improved neurosurgery sales to offset underperformance in Tissue Reconstruction. Essig also acknowledged that, despite improved product availability, pressures in Tissue Reconstruction—especially in UBM and Integra Skin—created additional volatility during the quarter.
Looking ahead, Integra LifeSciences’ updated guidance reflects continued headwinds from the Cincinnati site and a cautious view on Tissue Reconstruction recovery. Management expects revenue challenges to persist into the next quarter, with CFO Lea Knight citing the need for “stronger execution by the team, expanded professional education and clinical activity, better account coverage, and greater leverage across the full portfolio.” Knight also noted that incremental interest expense from recent refinancing and ongoing gross margin pressures will weigh on earnings, though contributions from new products like SurgiMend and cost discipline are expected to partially offset these factors.
Key insights from management’s remarks
Management attributed Q3 results to ongoing Cincinnati manufacturing disruptions, uneven Tissue Reconstruction recovery, and strong neurosurgery performance, while the revised outlook was shaped by continued operational headwinds and product mix challenges.
-
Cincinnati facility disruption: The flooding event at Integra’s Cincinnati manufacturing site had a larger-than-anticipated impact, particularly on the MAYFIELD neurosurgery product line. Supply chain recovery is underway, but full manufacturing capacity is not expected until mid-2027.
-
Mixed Tissue Reconstruction recovery: While PriMatrix and DuraSorb products showed meaningful growth, Integra Skin remained flat and UBM (especially MicroMatrix) faced continued competitive and execution pressure, resulting in overall segment softness.
-
Neurosurgery momentum: The neurosurgery business, supported by products like CereLink, Certas Plus, and DuraSeal, delivered robust growth and helped offset weaknesses elsewhere. Management emphasized resilient demand and strong international expansion in this segment.
-
Commercial focus and execution: Management implemented clearer priorities, improved account planning, and more coordinated customer engagement, aiming to drive more consistent growth and recover lost share in affected segments.
-
Balance sheet and refinancing: Strong cash generation and a recent $2.1 billion debt refinancing improved liquidity and financial flexibility, although higher interest expense will be a headwind for earnings in the coming quarters.
Drivers of future performance
Management’s outlook is shaped by extended Cincinnati recovery, persistent Tissue Reconstruction challenges, and new product launches, with cost discipline and interest expense also affecting profitability.
-
Cincinnati recovery timeline: The manufacturing disruption from the Cincinnati flood will continue to impact revenue and margins through at least the first half of next year, with management planning for normal operations to resume by mid-2027. Insurance recoveries may help partially offset some lost profits but are subject to approval timelines.
-
Tissue Reconstruction headwinds and new launches: Base Tissue Reconstruction is expected to remain flat into next year as competitive pressure and slow share recapture persist, especially in UBM and Integra Skin. However, the upcoming relaunch of SurgiMend and continued growth from PriMatrix are expected to contribute positively once supply and regulatory milestones are met.
-
Margin and cost management: Management anticipates continued gross margin pressure from product mix and lost revenue, compounded by higher interest expense following refinancing. Offsetting factors include annualized cost savings from operational transformation projects, reduced remediation and consulting costs, and productivity improvements as all products return to market.
Catalysts in upcoming quarters
In upcoming quarters, the StockStory team will closely monitor (1) the pace of Cincinnati facility remediation and any earlier-than-expected production resumption, (2) the commercial relaunch and adoption of SurgiMend in Tissue Reconstruction, and (3) sustained neurosurgery momentum, especially in international markets. Progress on cost savings initiatives and mitigation of margin pressures will also be important signposts.
Integra LifeSciences currently trades at $11.81, down from $13.33 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
High quality stocks for all market conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
